The death rate in the group treated with daraxonrasib was 60% lower than those on chemotherapy. This is hailed as a major ...

Daraxonrasib is effective for patients with RAS-mutant and other metastatic pancreatic ductal adenocarcinomas (mPDACs).

Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 15, the price target on Tango Therapeutics Inc. (NASDAQ:TNGX) was ...

An international phase 3 clinical trial has found that an investigational oral medication (a daily pill) doubled the median ...

Patients with advanced pancreatic cancer who had already failed at least one round of chemotherapy lived roughly twice as ...

An expert highlights phase 3 trial data evaluating darovasertib as targeted therapy for advanced metastatic pancreatic ...

Pancreatic adenocarcinoma remains one of the most aggressive and difficult-to-treat solid tumor malignancies, with a high mortality-to-incidence ratio. Globally, pancreatic cancer ranks 12th in terms ...

BOSTON — Key DNA and chromosomal and immune cell changes in early-stage lung adenocarcinoma show significant associations with outcomes, representing potentially important early predictors to guide ...

A study by the University of Barcelona has discovered why the two main types of lung cancer—adenocarcinoma of the lung and ...